p53R2 is a newly identified subunit of ribonucleotide reductase (RR) and plays a crucial role in supplying precursors for DNA repair in a p53-dependent manner. In our current work, all three human RR subunit proteins (p53R2, hRRM2, and hRRM1) were prokaryotically expressed and highly purified. Using an in vitro [ 3 H]CDP reduction assay, the activity of RR reconstituted with either p53R2 or hRRM2 was found to be time, concentration, and hRRM1 dependent. The kinetic activity of p53R2-containing RR was about 20 -50% lower than that of hRRM2-containing RR. Using a synthetic heptapeptide to inhibit RR activity, it was shown that p53R2 bound to hRRM1 through the same COOHterminal heptapeptide as hRRM2. However, hRRM2 had a 4.76-fold higher binding affinity for hRRM1 than p53R2, which may explain the reduced RR activity of p53R2 relative to hRRM2. Of interest, p53R2 was 158-fold more susceptible to the iron chelator deferoxamine mesylate than hRRM2, although the iron content of the two proteins determined by atomic absorption spectrometer was almost the same. To the contrary, p53R2 was 2.50-fold less sensitive than hRRM2 to the radical scavenger hydroxyurea, whereas EPR showed similar spectra of the tyrosyl radical in two proteins. Triapine, a new RR inhibitor, was equally potent for p53R2 and hRRM2. These inhibition studies showed that the iron center and tyrosyl radical are involved in RR activity for both p53R2 and hRRM2. The susceptibility differences to RR inhibitors between p53R2 and hRRM2 may lead to a new direction in drug design for human cancer treatment.
Introduction
Ribonucleotide reductase (RR) is the unique enzyme responsible for the reduction of all four ribonucleotides to their corresponding deoxyribonucleotides (dNTPs), which are the building blocks for DNA replication and repair in all living cells (1) . Human RR is a tetramer complex, composed of two non-identical homodimers, hRRM1 and hRRM2 (R1and R2 in mouse) . The large subunit hRRM1 (87 kD) harbors the catalytic site, allosteric effector-binding sites, and redox active disulfides that participate in the reduction of substrates, whereas the small subunit hRRM2 (43 kD) contains an oxygen-linked di-ferric center and one tyrosyl radical per monomer that are essential for enzymatic activity (1, 2) .
p53R2, a 351-amino acid peptide (39 kD), is a newly identified hRRM2 homolog (ϳ80%) and plays a crucial role in supplying dNTPs for DNA repair (3, 4) . Several known functional domains in mouse R2 are also conserved in p53R2 (2-7), including the iron ligands, the radical site tyrosine, the hydrophobic pocket surrounding the tyrosyl radical site, the radical transfer pathway from small subunit to large subunit, the COOH-terminal sequence for binding to large subunit, and the hydrophobic channel from the surface to the interior of the protein. However, the actual functions of these domains in p53R2 for RR activity are not confirmed. The major sequence difference between the two small subunits is that p53R2 lacks 33 amino acid residues in its NH 2 terminus (8) . The human p53R2 gene contains a p53-binding site in intron 1. The expression of p53R2, but not hRRM2, is induced by UV light, ␥-irradiation, or DNA-damaging agents in a p53-dependent manner (3, 4) . p53R2 forms an active RR in vitro with R1, and the expression of the R1 is induced in resting cells after UV irradiation (9) . These findings lead to the hypothesis that there are two pathways in human cells to supply dNTPs for DNA synthesis: one through the activity of hRRM2, involved in normal maintenance of dNTPs for DNA replication during the S-phase in a cell cycle-dependent manner, and the other through p53R2, supplying dNTPs for DNA repair in G 0 -G 1 cells in a p53-dependent manner (10, 11) . Recently, our lab found that in p53 mutant and null cells, hRRM2 complements p53R2 in response to UV-induced DNA repair (12) . Furthermore, p53 can interact with p53R2 and hRRM2 at the protein level to regulate RR activity (13) . However, it is still unclear how the expression and activity of the two small subunits are coordinately regulated in cells. It has been shown that alterations in RR levels, in particular overexpression of hRRM2, can have significant effects on the biological properties of cells, tumor development and metastasis, and drug resistance (14, 15) . A study of Rrm2b (encoding p53R2)-null mice showed that impairment of the p53R2-involved DNA repair pathway enhances the frequency of spontaneous mutations and activates p53-dependent apoptotic pathway(s) (16) . However, the role that p53R2 plays in the development of human cancers remains to be elucidated.
Because RR is overexpressed in cancer cells, the development of RR inhibitors may prove useful as anticancer drugs. A number of compounds have been characterized as RR inhibitors. The first category targets hRRM2 by quenching the tyrosyl radical and/or affecting the iron center, such as hydroxyurea (17), 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (triapine), and deferoxamine mesylate (DFO; Ref. 18 ). The second category of drugs targets hRRM1 by disturbing binding of allosteric effectors or using nucleoside analogues, such as 2,2Ј-difluorodeoxycytidine (19) . The third category includes peptidomimetic drugs that competitively inhibit the binding of the small subunit to the large subunit (20) and inhibitors that disturb the radical transfer pathway (7). p53R2, functioning in a p53-dependent DNA repair pathway, may have the potential to be considered as a new therapeutic target for human cancer (7, 11) . Furthermore, because p53R2 and hRRM2 play different roles in cells, inhibitors specific for each subunit could have different clinical values. However, no p53R2 inhibitors have been characterized thus far.
In our current work, a simple and rapid procedure was developed for the expression and purification of all three subunits of RR. Using an in vitro RR assay, we examined the enzymatic properties and mechanisms of p53R2 including its interaction with the large subunit and its response to RR inhibitors. These findings may provide a basis for the design and screening of more effective and subunit-selective RR inhibitors for human cancer therapy.
Materials and Methods
Plasmid Construction. Total RNA was isolated from human oropharyngeal carcinoma KB cells. The coding sequences of human p53R2, hRRM2, and hRRM1 proteins were obtained by reverse transcription-PCR using the following primer pairs: (1) hRRM1: 5Ј-CAGCGGCCGCGATGCATGTGAT-CAAGCGA (with a NotI enzyme digestion site) and 3Ј-AAGCGGCCGCT-CAGGATCCACACATCAG (with a NotI enzyme digestion site); (2) hRRM2: 5Ј-ATCCGGATCCACTATGCTCTCCCTCCGTGT (with a BamHI enzyme digestion site) and 3Ј-GCTTAAGCTTATTTAGAAGTCAGCATCCAAG (the NotI enzyme digestion site comes from pDrive vector); and (3) p53R2: 5Ј-TCGGATCCATGGGCGACCCGGAAAGG (with a BamHI enzyme digestion site) and 3Ј-GCGGCCGCTTAAAAATCTGCATCCAA (with a NotI enzyme digestion site). The PCR products were purified and inserted into the pDrive cloning vector (Qiagen, Valencia, CA) via U-A ligation. After restriction digestion, the coding sequence of each RR subunit was then cloned in-frame with an NH 2 -terminal 6ϫ His-tag into the prokaryotic expression vector pET28 (Novagen, Madison, WI). All constructs (pET28a-p53R2, pET28a-hRRM2, and pET28b-hRRM1) were verified by DNA sequencing.
Protein Expression and Purification. Three recombinant RR subunit proteins were expressed from BL21 (DE3) bacteria (Stratagene, La Jolla, CA) and were purified using Ni-resin (Qiagen) affinity chromatography based on Qiagen's protocol. For p53R2 protein, an overnight culture of the transformed bacteria was diluted 50-fold in 1 liter of Luria broth medium containing 30 g/ml kanamycin and grown at 37°C for 4 h and then induced by 1 mM isopropyl-1-thio-␤-D-galactopyranoside for an additional 3 h at 30°C. After harvesting by centrifugation, the cell pellets were disrupted by incubation with Bugbuster and benzonase nuclease (Qiagen) at 4°C for 30 min with vigorous agitation, and the lysate was centrifuged at 16,000 ϫ g for 30 min at 4°C. The clear supernatant was incubated with Ni-resin at 4°C for 30 min, loaded on a column, washed with at least 30-fold bed volume of 50 mM NaH 2 PO 4 , 800 mM NaCl, 50 mM imidazole, pH 7.0, 0.1% Triton X-100, and 10 mM 2-mercaptoethanol, and finally eluted with 50 mM NaH 2 PO 4 , 300 mM NaCl, and 125 mM imidazole, pH 7.0. The eluates were thoroughly dialyzed against 2000 sample volumes of 25 mM Tris-HCl, pH 7.4, at 4°C overnight. Expression and purification of the hRRM2 and hRRM1 proteins were performed in the same way as for p53R2. The proteins were placed in aliquots and frozen at Ϫ70°C. The RR activity of the two small subunit proteins was stable within a 5-month period, and after that, the activity of p53R2 gradually decreased.
Qualitative and Quantitative Analysis of Protein Preparations. Protein concentration was determined using the Bio-Rad Protein Assay kit (Bio-Rad, Hercules, CA). Protein purity was determined by densitometric scanning of the Coomassie-stained SDS-PAGE gel. For immunoblotting, protein samples were analyzed using goat anti-p53R2, hRRM2, and hRRM1 antibodies (Santa Cruz Biotechnology, Santa Cruz, CA). For MS/MS (tandem mass spectrometry), protein bands were cut from a 10% SDS-PAGE gel, in-gel digested with trypsin, and examined by HPLC/MS/MS and SEQUEST searching at the City of Hope National Medical Center Mass Spectrometry Core Facility.
Atomic Absorption Spectrometry. A Perkin-Elmer atomic absorption spectrometer equipped with a HGA850 graphite furnace was used for measurement of iron content at the City of Hope National Medical Center Pharmacoanalytic Core Facility. PE Pure Iron standard solution (Perkin-Elmer, Norwalk, CT) was 2-fold serially diluted from 50 -1000 g/l to construct the standard curve (y ϭ 0.00052 ϫ ϩ 0.0027; x, concentration; y, absorbance; r ϭ 0.993). The purified proteins were thoroughly dialyzed and diluted 1:5 with demineralized water. Iron content was expressed as g of iron per mol of each RR subunit protein.
EPR (Electron Paramagnetic Resonance) Spectra. X-band EPR spectra were measured with a Bruker EMX spectrometer equipped with an Oxford helium cryostat at the Department of Chemistry of The California Institute of Technology. Purified samples of p53R2 and hRRM2 proteins were frozen in liquid nitrogen before insertion in the cavity. Instrumental parameters were: T, 20 K; microwave frequency, 9.376 GHz; microwave power, 0.5 mW; modulation amplitude, 4 gauss; and modulation frequency, 100 KHz.
RR Activity Assay in Vitro. RR activity was measured using the [ 3 H]CDP reduction assay as described previously with a slight modification (17) . Briefly, the reaction mixture contained 0.125 M [ 3 H]CDP, 50 mM HEPES (pH 7.2), 6 mM DTT, 4 mM magnesium acetate, 2 mM ATP, 0.05 mM CDP, 100 mM KCl, 0.24 mM NADPH, and different amounts of purified proteins in a final volume of 100 l. After incubation at 37°C for a desired time and dephosphorylation, samples were analyzed by HPLC and liquid scintillation counting. To determine enzymatic specific activity, p53R2 or hRRM2 was 2-fold serially diluted (0.625-10 g) and incubated with 30 g of hRRM1 at 37°C for 15 min. Specific activity was calculated as nmol of dCDP formed/ min/mg protein.
RR Inhibitor Preparation and Test. The heptapeptide Ac-FTLDADF was synthesized by the City of Hope National Medical Center DNA/RNA/ Peptide Synthesis Facility. DFO and hydroxyurea were obtained from Sigma. Triapine was a gift from Vion Pharmaceutical (New Haven, CT). For assays of the inhibition of RR activity, each inhibitor was serially diluted in 25 mM Tris-HCl (pH 7.4), incubated with purified RR subunit proteins at room temperature for 30 min, added directly to the reaction buffer, and analyzed for RR activity as described above. RR activity in the absence of any inhibitor was used as a control. Results are expressed as a percentage of the control value (relative RR activity). IC 50 s were determined by interpolation of the plotted data to show the inhibitor concentration that produced 50% inhibition of RR activity.
Statistics. Results are presented as the mean Ϯ SD of three separate experiments, each performed in duplicate. The significance of the data was determined using Student's t test (two-tail). P Ͻ 0.01 was deemed significant.
Results and Discussion
Expression and Purification of Three Human RR Subunit Proteins. Human p53R2, hRRM2, and hRRM1 proteins were all expressed using the pET28-BL21(DE3) prokaryotic system except that different restriction sites were used for each construction and were purified to ϳ90% purity using one-step Ni-resin affinity chromatography (Fig. 1) . Protein yields were 20, 10, and 2 mg/l of induced bacterial culture for p53R2, hRRM2, and hRRM1 proteins. Reconstitution of RR activity was straightforward by mixing purified p53R2 or hRRM2 with hRRM1 and did not require regeneration of the irontyrosyl radical center that is necessary for RR activity (9, 21) . Use of the same expression and purification system for all three subunits greatly increased the comparability of enzyme activity between the two small subunits. A slightly smaller band copurified with the 42.5 kD His-tagged p53R2 band regardless of the purification stringency or the use of protease inhibitors. Both bands were examined by HPLC/ MS/MS. SEQUEST matching confirmed that both bands belonged to human p53R2 with 65 and 48% sequence coverage for the major and the smaller bands, respectively. Therefore, the small band may represent partially degraded p53R2 preparation.
RR Activity Is Time, Concentration, and hRRM1 Dependent But Activity with Human p53R2 Is Lower Than with hRRM2.
The kinetic profile of RR activity reconstituted with p53R2 was compared with that of RR reconstituted with hRRM2. When 2.5 g of each small subunit were combined with an excess of hRRM1, the reaction rate with p53R2 was ϳ51% of that with hRRM2 at the first time point (2.5 min; Fig. 2A) . However, the difference in reaction rates decreased with time. After 20 min, the rate with p53R2 was ϳ80% of that with hRRM2. When a larger amount of each small subunit (5 g) was used, a plateau was reached more rapidly than with 2.5 g, where RR activity with p53R2 peaked at ϳ88% of that with hRRM2 by 15 min (Fig. 2B ). An excess of p53R2 or hRRM2 was mixed with various amounts of hRRM1 and assayed for RR activity (Fig. 2C) . RR activity increased as the amount of hRRM1 increased, indicating that RR activity with either p53R2 or hRRM2 was highly dependent on hRRM1 concentration. However, RR activity with p53R2 was consistently lower than that with hRRM2, regardless of the concentration of hRRM1, suggesting that the differences in activity could be attributed to enzymatic properties of the small subunits. The specific activity for RR reconstituted with p53R2 (51.9 Ϯ 1.17 nmol/min/mg) was significantly lower than that reconstituted with hRRM2 (75.0 Ϯ 2.21 nmol/min/mg; P Ͻ 0.01).
The Binding Affinity of Human p53R2 to hRRM1 Was Weaker Than hRRM2. The COOH-terminal heptapeptide sequence (FTLDADF) of hRRM2 is completely conserved in human p53R2 (Fig. 3, A and B) . Therefore, we used the synthetic heptapeptide to test the interaction between p53R2 and hRRM1 proteins. Our results showed that RR activity with either p53R2 or hRRM2 was inhibited in a dose-dependent mode (Fig. 3C) . The IC 50 of the synthetic heptapeptide for p53R2 was 48.3 Ϯ 5.66 M, whereas the IC 50 for hRRM2 was 230 Ϯ 12.4 M, 4.76-fold higher than that of p53R2. These results demonstrate that human p53R2 binds to hRRM1 through the same COOH-terminal sequence as hRRM2 and that they share the same binding domain on hRRM1. The weaker binding affinity of p53R2 for hRRM1 may explain why the RR activity of p53R2 was lower than that of hRRM2.
Human p53R2 Was More Susceptible to Iron Chelation DFO Than hRRM2. The conserved iron ligands in human p53R2 sequence was shown in Fig. 3A . Using atomic absorption spectrometry, we measured the iron contents of p53R2, hRRM2, and hRRM1 and found them to be 30.7 Ϯ 1.02, 31.8 Ϯ 3.03, and 68.3 Ϯ 2.03 g/mol protein, respectively. DFO, an iron chelator, is currently used in treatment of diseases related to iron overload and has been shown to have antiproliferative effects attributed to inhibition of RR activity (18) . We found that RR activity of both small subunits was inhibited by DFO, but the IC 50 of DFO for p53R2 (3.16 Ϯ 0.213 M) was 158-fold lower than that of hRRM2 (500 Ϯ 35.1 M; Fig. 4A ). These results indicate that the iron center is important for the RR activity of both p53R2 and hRRM2. However, because the iron content of the two small subunits was not significantly different, the greater sensitivity of p53R2 to DFO requires further elucidation. This difference Fig. 1 . In vitro expression and purification of human RR subunits. A, 10% SDS-PAGE analysis of the purified recombinant proteins by one-step Ni-resin affinity chromatography. Lane 1, molecular mass marker; Lane 2, hRRM1 (5 g); Lane 3, hRRM2 (2.5 g); Lane 4, p53R2 (2.5 g). B, immunoblot confirmation of protein preparations. Fig. 2 . Activity of RR holoenzyme reconstituted with human p53R2 or hRRM2. 2.5 g (A) or 5 g (B) of p53R2 or hRRM2 was mixed with 20 g of hRRM1 and assayed for RR activity. Samples were incubated at 37°C for the indicated times, and RR activity was assayed as described in "Materials and Methods." C, hRRM1 was 2-fold serially diluted (0.938 -15 g) and incubated with an excess of p53R2 or hRRM2 (25 g) at 37°C for 30 min and then assayed for RR activity. The data are presented as the means of three separate experiments, each performed in duplicate; bars, SD. ‫,ء‬ statistical significance (P Ͻ 0.01).
may be attributable to a more accessible iron-radical center in p53R2 to the environment, or the iron center of p53R2 may be less stable than that of hRRM2. It has been suggested that DFO inhibits RR activity and cell growth by chelating the intracellular iron pool rather than by directly attacking the iron-radical center (22) . However, our in vitro data showed that the loss of RR activity resulted from the direct chelation of the iron within the proteins.
Human p53R2 Was Less Sensitive to the Radical Scavenger Hydoxyurea Than hRRM2. The sequence site of Tyr-138 in human p53R2 (Fig. 3A) corresponds to the radical site tyrosine in hRRM2 (Tyr-176; Ref. 3) . We found that the EPR spectrum of the tyrosyl radical in p53R2 protein is almost identical with the radical in hRRM2 protein (Fig. 4B) , indicating that both subunits may employ the same tyrosyl radical mechanism for enzymatic activity. Hydroxyurea has been widely used in human cancer treatment and is known to specifically inhibit hRRM2 by reducing the tyrosyl radical and the iron center (17, 23) . We showed that RR activity of p53R2 was inhibited by hydroxyurea in a dose-dependent manner, similar to the inhibition of hRRM2 (Fig. 4C) . The IC 50 of hydroxyurea for p53R2 (2.48 Ϯ 0.274 mM) was 2.50-fold higher than that of hRRM2 (0.991 Ϯ 0.102 mM). This result indicates that, in contrast to their relative sensitivity to DFO, p53R2 was less sensitive to hydroxyurea than hRRM2.
Triapine is a new RR inhibitor currently being tested in phase II clinical trials for cancer therapy (24) . Our results showed that triapine directly inactivated the RR activity of p53R2 and hRRM2 with almost equal efficiency (Fig. 4D) . The IC 50 of triapine was 112 Ϯ 8.83 nM for p53R2 and 144 Ϯ 7.63 nM for hRRM2. Of the three RR inhibitors tested in this study, triapine was the most potent (Table 1 ). This result is consistent with the data comparing the efficiency of RR inhibitors in cancer cells (18, 24, 25) . The antiproliferative activity of triapine in intact cells involves multiple inhibitory mechanisms. It not only has iron chelation efficacy that is similar to that of DFO but is capable of generating reactive oxygen species after binding iron that may result in destruction of the tyrosyl radical (24, 25) . It is known that the low efficiency of hydroxyurea is associated with its physicochemical properties, e.g., very high hydrophilicity and small molecular size (26). In contrast, the hydrophobicity and structural feature of triapine may also contribute to its marked effect on RR activity.
In summary, we expressed and purified three RR subunit proteins using a simple and rapid procedure and obtained high RR activity by straightforward reconstitution of p53R2 or hRRM2 with hRRM1 in vitro. We showed that the reaction rate of p53R2 was lower than that of hRRM2, which may be attributable to its reduced binding affinity to hRRM1. Enzymatic inhibition studies showed that the iron center and the tyrosyl radical were involved in the RR activity of both p53R2 and hRRM2. However, the responses of two small subunits to the inhibitors were quite different, perhaps attributable to differences in protein structure or to differences in the molecular mechanisms of the inhibitors. Future work will focus on determining the crystal structures of three human RR subunits to further elucidate the inhibition mechanisms. Study of the enzyme kinetics of RR subunits and the mechanisms of interaction with inhibitors may lead to the design of more effective and subunit-selective RR inhibitors for human cancer therapy. Fig. 4 . Response of human p53R2 and hRRM2 to RR inhibitors. A, inhibition curve of DFO (5-fold serially diluted from 2.40 M to 37.5 mM). B, EPR spectra of the tyrosyl radical in human p53R2 (a) and hRRM2 (b) proteins. The spectra were recorded as described in "Materials and Methods." C, inhibition curve of hydroxyurea (2-fold serially diluted from 78.1 M to 5 mM). D, inhibition curve of triapine (5-fold serially diluted from 16 nM to 10 M). Each serially diluted inhibitor was incubated with 2.5 g of hRRM2 or p53R2 and 10 g of hRRM1 and assayed for RR activity as described in "Materials and Methods." The data are presented as the means of three separate experiments, each performed in duplicate; bars, SD. ‫,ء‬ statistical significance (P Ͻ 0.01). 
